All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

hydrocodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1386	125-29-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: hydrocodone dihydrocodeinone hydrocodon multacodin hydrocodone bitartrate hydrocodone polistirex	Narcotic analgesic related to CODEINE, but more potent and more addicting by weight. It is used also as cough suppressant. Molecular weight: 299.37 Formula: C18H21NO3 CLOGP: 1.13 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 38.77 ALOGS: -2.57 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
15	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	62.50 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	10.20 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.15 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	80 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
March 23, 1943	FDA	ENDO PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	840.54	10.62	858	52994	131031	50420241
Cholecystitis chronic	440.07	10.62	212	53640	9457	50541815
Toxicity to various agents	343.43	10.62	721	53131	211778	50339494
Drug hypersensitivity	272.02	10.62	729	53123	250281	50300991
Cardio-respiratory arrest	234.62	10.62	288	53564	53604	50497668
Injury	193.10	10.62	249	53603	48676	50502596
Emotional distress	184.64	10.62	188	53664	28475	50522797
Cholelithiasis	168.57	10.62	205	53647	37768	50513504
Respiratory arrest	163.41	10.62	180	53672	29829	50521443
Drug abuse	157.26	10.62	251	53601	59595	50491677
Gallbladder disorder	156.34	10.62	135	53717	16607	50534665
Anxiety	152.51	10.62	475	53377	177131	50374141
Contraindicated product administered	140.02	10.62	4	53848	148954	50402318
Deep vein thrombosis	131.32	10.62	260	53592	73044	50478228
Maternal exposure during pregnancy	118.83	10.62	15	53837	159763	50391509
Depression	112.34	10.62	409	53443	165014	50386258
Intentional product misuse	109.26	10.62	186	53666	46548	50504724
Drug intolerance	101.95	10.62	53	53799	219051	50332221
Biliary dyskinesia	95.52	10.62	49	53803	2501	50548771
Synovitis	93.63	10.62	11	53841	123854	50427418
Off label use	90.07	10.62	236	53616	474190	50077082
Hand deformity	89.59	10.62	4	53848	100195	50451077
Systemic lupus erythematosus	89.55	10.62	20	53832	140602	50410670
Glossodynia	88.01	10.62	10	53842	115559	50435713
Infusion related reaction	86.60	10.62	36	53816	169521	50381751
Treatment failure	84.83	10.62	21	53831	137616	50413656
Gallbladder injury	76.41	10.62	34	53818	1260	50550012
Lower respiratory tract infection	73.08	10.62	8	53844	95193	50456079
Pulmonary embolism	72.83	10.62	256	53596	101448	50449824
Drug ineffective	69.46	10.62	550	53302	818783	49732489
Cardiac arrest	68.23	10.62	220	53632	83431	50467841
Joint swelling	63.42	10.62	102	53750	245184	50306088
Drug withdrawal syndrome	62.84	10.62	103	53749	24978	50526294
Pericarditis	61.98	10.62	6	53846	78683	50472589
Accidental death	60.98	10.62	32	53820	1712	50549560
Drug dependence	60.48	10.62	89	53763	19670	50531602
Wound	56.40	10.62	21	53831	105773	50445499
Death	55.91	10.62	560	53292	324819	50226453
Accidental overdose	55.54	10.62	85	53767	19448	50531824
Inadequate analgesia	54.58	10.62	34	53818	2524	50548748
Overdose	49.59	10.62	224	53628	99503	50451769
Discomfort	47.77	10.62	28	53824	108352	50442920
Rash	47.72	10.62	272	53580	437199	50114073
Neutropenia	45.77	10.62	54	53798	147911	50403361
Product use issue	45.76	10.62	55	53797	149420	50401852
C-reactive protein increased	45.34	10.62	8	53844	66466	50484806
Anhedonia	44.83	10.62	53	53799	9471	50541801
Exposure during pregnancy	44.48	10.62	38	53814	120977	50430295
Drug abuser	44.32	10.62	31	53821	2797	50548475
Gallbladder hypofunction	41.62	10.62	17	53835	508	50550764
Rheumatoid factor positive	41.46	10.62	3	53849	49856	50501416
Biliary colic	40.38	10.62	31	53821	3228	50548044
Arthropathy	39.53	10.62	67	53785	157839	50393433
Abdominal discomfort	38.14	10.62	123	53729	231518	50319754
Nasopharyngitis	37.99	10.62	94	53758	192833	50358439
Coronary artery disease	37.88	10.62	92	53760	29634	50521638
Cholecystitis	37.53	10.62	59	53793	13812	50537460
Hepatic enzyme increased	37.50	10.62	55	53797	137325	50413947
Helicobacter infection	36.12	10.62	5	53847	49697	50501575
Insomnia	34.96	10.62	311	53541	174554	50376718
Scar	34.40	10.62	52	53800	11766	50539506
Mental status changes	33.83	10.62	100	53752	36172	50515100
Condition aggravated	33.80	10.62	182	53670	296876	50254396
Back pain	33.61	10.62	370	53482	219660	50331612
Respiratory depression	32.37	10.62	51	53801	11959	50539313
Pyrexia	32.09	10.62	255	53597	379948	50171324
Febrile neutropenia	31.99	10.62	34	53818	97633	50453639
Rheumatoid arthritis	31.65	10.62	110	53742	202440	50348832
Acute lung injury	30.95	10.62	19	53833	1374	50549898
Cerebrovascular accident	30.72	10.62	189	53663	94491	50456781
Cholesterosis	30.71	10.62	13	53839	426	50550846
Gallbladder cholesterolosis	30.15	10.62	15	53837	717	50550555
Chest pain	29.60	10.62	303	53549	176579	50374693
Therapeutic product effect decreased	29.42	10.62	63	53789	135987	50415285
Muscle injury	28.77	10.62	3	53849	37108	50514164
Alopecia	28.49	10.62	149	53703	244898	50306374
Hypersensitivity	27.81	10.62	126	53726	215035	50336237
Infection	27.65	10.62	93	53759	172861	50378411
Muscle spasms	27.01	10.62	227	53625	125326	50425946
Intervertebral disc protrusion	26.93	10.62	64	53788	20329	50530943
Dependence	25.82	10.62	19	53833	1856	50549416
Drug screen positive	25.02	10.62	24	53828	3378	50547894
Feeling abnormal	24.45	10.62	222	53630	125270	50426002
Intervertebral disc degeneration	24.38	10.62	48	53804	13413	50537859
Nausea	24.29	10.62	948	52904	704450	49846822
Folliculitis	24.12	10.62	6	53846	39219	50512053
Electrocardiogram QT prolonged	23.43	10.62	13	53839	51873	50499399
Poisoning	23.34	10.62	45	53807	12384	50538888
Swelling	22.86	10.62	123	53729	200749	50350523
Thrombocytopenia	22.26	10.62	66	53786	127607	50423665
Cardiac failure	22.19	10.62	29	53823	76011	50475261
Migraine	21.78	10.62	146	53706	75134	50476138
Pain in extremity	21.61	10.62	409	53443	272456	50278816
Uterine perforation	21.24	10.62	30	53822	6385	50544887
Renal impairment	20.92	10.62	30	53822	75631	50475641
Mental disorder	20.86	10.62	61	53791	21930	50529342
Drug interaction	20.69	10.62	126	53726	199495	50351777
Product use in unapproved indication	20.10	10.62	60	53792	115759	50435513
Musculoskeletal stiffness	19.90	10.62	70	53782	128411	50422861
Leukopenia	19.45	10.62	26	53826	67502	50483770
Gamma-glutamyltransferase increased	19.27	10.62	4	53848	29619	50521653
Back injury	18.98	10.62	30	53822	7055	50544217
Sleep disorder due to general medical condition, insomnia type	18.97	10.62	5	53847	31442	50519830
Thrombosis	18.44	10.62	112	53740	55721	50495551
Pain	18.26	10.62	771	53081	578132	49973140
Hepatic function abnormal	18.24	10.62	6	53846	32675	50518597
Chronic obstructive pulmonary disease	18.17	10.62	108	53744	53327	50497945
Abortion spontaneous	18.10	10.62	11	53841	41761	50509511
Road traffic accident	18.01	10.62	62	53790	24290	50526982
Interstitial lung disease	17.98	10.62	18	53834	53158	50498114
Hepatocellular injury	17.96	10.62	3	53849	25944	50525328
Gastrooesophageal reflux disease	17.95	10.62	141	53711	76287	50474985
Cholecystectomy	17.86	10.62	34	53818	9269	50542003
Abnormal dreams	17.67	10.62	34	53818	9343	50541929
Cholecystitis acute	17.55	10.62	29	53823	7077	50544195
Peripheral swelling	17.39	10.62	138	53714	205798	50345474
Lactic acidosis	17.14	10.62	7	53845	33348	50517924
Respiratory muscle weakness	17.13	10.62	6	53846	116	50551156
Withdrawal syndrome	16.88	10.62	49	53803	17541	50533731
Ill-defined disorder	16.83	10.62	20	53832	54634	50496638
Device expulsion	16.61	10.62	5	53847	28817	50522455
Purpura senile	16.51	10.62	9	53843	520	50550752
Tarsal tunnel syndrome	16.35	10.62	9	53843	530	50550742
Dehydration	16.28	10.62	240	53612	152209	50399063
Memory impairment	15.76	10.62	141	53711	79219	50472053
Peptic ulcer	15.74	10.62	20	53832	3846	50547426
Hypoaesthesia	15.46	10.62	205	53647	127052	50424220
Cholestasis	15.39	10.62	4	53848	25397	50525875
Tooth loss	14.99	10.62	25	53827	6145	50545127
Drug tolerance	14.63	10.62	22	53830	4954	50546318
Septic shock	14.53	10.62	24	53828	57151	50494121
Fear	14.42	10.62	41	53811	14508	50536764
Emotional disorder	14.41	10.62	36	53816	11800	50539472
Erythema	14.34	10.62	94	53758	146320	50404952
Neck injury	14.34	10.62	13	53839	1704	50549568
Lumbosacral plexopathy	14.25	10.62	3	53849	6	50551266
Pulmonary infarction	14.12	10.62	15	53837	2383	50548889
Vestibular disorder	13.42	10.62	11	53841	1258	50550014
Resorption bone increased	13.37	10.62	10	53842	1001	50550271
Extradural haematoma	13.22	10.62	12	53840	1575	50549697
Hyponatraemia	13.19	10.62	55	53797	96084	50455188
Blood pressure systolic increased	13.17	10.62	11	53841	35438	50515834
Major depression	13.02	10.62	25	53827	6859	50544413
Accidental poisoning	12.84	10.62	8	53844	594	50550678
Myocardial infarction	12.79	10.62	148	53704	88879	50462393
Stomatitis	12.69	10.62	60	53792	101284	50449988
Abdominal pain	12.64	10.62	335	53517	235893	50315379
Hyperlipidaemia	12.48	10.62	44	53808	17446	50533826
Hyperkalaemia	12.39	10.62	20	53832	48069	50503203
Toxic leukoencephalopathy	12.36	10.62	8	53844	635	50550637
Bone marrow failure	12.36	10.62	7	53845	27617	50523655
Altered state of consciousness	12.27	10.62	4	53848	21906	50529366
Nervousness	12.18	10.62	60	53792	27591	50523681
Product complaint	12.04	10.62	33	53819	11433	50539839
Rotator cuff syndrome	11.90	10.62	33	53819	11511	50539761
Nail growth abnormal	11.82	10.62	7	53845	474	50550798
Osteonecrosis	11.49	10.62	51	53801	22466	50528806
Drug-induced liver injury	11.36	10.62	8	53844	28087	50523185
Restless legs syndrome	11.34	10.62	40	53812	15857	50535415
Fat intolerance	11.32	10.62	3	53849	21	50551251
Muscle atrophy	11.29	10.62	22	53830	6099	50545173
Psychological trauma	11.28	10.62	9	53843	991	50550281
Transverse sinus thrombosis	11.27	10.62	7	53845	517	50550755
Muscle tightness	11.21	10.62	30	53822	10250	50541022
Blood pressure fluctuation	11.14	10.62	13	53839	35810	50515462
Multiple organ dysfunction syndrome	11.13	10.62	23	53829	50314	50500958
Red blood cell sedimentation rate increased	11.09	10.62	9	53843	29407	50521865
Intervertebral disc disorder	11.04	10.62	18	53834	4342	50546930
Chronic fatigue syndrome	11.01	10.62	9	53843	1026	50550246
Crying	11.00	10.62	47	53805	20369	50530903
Intestinal ischaemia	10.94	10.62	23	53829	6734	50544538
Tendon disorder	10.90	10.62	20	53832	5302	50545970
Chronic kidney disease	10.82	10.62	76	53776	39695	50511577
Nerve injury	10.80	10.62	26	53826	8324	50542948
Compression fracture	10.79	10.62	21	53831	5816	50545456

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	467.11	11.69	519	30115	89727	29454166
Toxicity to various agents	261.67	11.69	563	30071	173098	29370795
Accidental overdose	212.71	11.69	163	30471	17430	29526463
Drug abuse	199.22	11.69	322	30312	79561	29464332
Cardio-respiratory arrest	181.21	11.69	242	30392	50359	29493534
Drug dependence	159.84	11.69	149	30485	20832	29523061
Respiratory arrest	133.85	11.69	149	30485	25684	29518209
Drug abuser	109.77	11.69	61	30573	3766	29540127
Off label use	89.83	11.69	108	30526	300692	29243201
Overdose	82.26	11.69	224	30410	79595	29464298
Drug withdrawal syndrome	81.78	11.69	97	30537	17887	29526006
Intentional product misuse	79.87	11.69	135	30499	34526	29509367
Anxiety	66.51	11.69	217	30417	85148	29458745
Depression	65.04	11.69	215	30419	84932	29458961
Inadequate analgesia	61.96	11.69	37	30597	2617	29541276
Emotional distress	55.17	11.69	70	30564	13825	29530068
Cardiac arrest	49.94	11.69	198	30436	85393	29458500
Respiratory depression	47.28	11.69	64	30570	13459	29530434
Drug hypersensitivity	45.47	11.69	165	30469	68241	29475652
Gun shot wound	44.57	11.69	22	30612	1063	29542830
Insomnia	43.73	11.69	195	30439	88566	29455327
Pyrexia	38.77	11.69	160	30474	287462	29256431
Coronary artery disease	34.96	11.69	113	30521	44077	29499816
C-reactive protein increased	34.70	11.69	3	30631	44260	29499633
Accidental death	33.25	11.69	23	30611	2095	29541798
Pain	33.05	11.69	296	30338	171136	29372757
Drug tolerance	32.91	11.69	23	30611	2130	29541763
Ventricular hypertrophy	31.90	11.69	30	30604	4234	29539659
Chest pain	31.40	11.69	211	30423	111762	29432131
Drug screen positive	30.88	11.69	28	30606	3773	29540120
Drug interaction	29.65	11.69	105	30529	197280	29346613
General physical health deterioration	29.44	11.69	38	30596	102819	29441074
Product use in unapproved indication	29.36	11.69	28	30606	86847	29457046
Myocardial infarction	28.65	11.69	204	30430	110092	29433801
Death	28.28	11.69	504	30130	341580	29202313
Substance abuse	28.22	11.69	35	30599	6752	29537141
Back pain	27.63	11.69	191	30443	102093	29441800
Lumbar radiculopathy	27.42	11.69	14	30620	727	29543166
Intervertebral disc degeneration	26.62	11.69	30	30604	5234	29538659
Dependence	25.65	11.69	15	30619	1020	29542873
Hepatic function abnormal	25.21	11.69	5	30629	39254	29504639
Arteriosclerosis	25.01	11.69	41	30593	10215	29533678
Neutropenia	24.07	11.69	64	30570	131647	29412246
Cardiac failure	24.05	11.69	28	30606	79259	29464634
Hypoaesthesia	23.74	11.69	114	30520	53353	29490540
Spinal osteoarthritis	23.63	11.69	31	30603	6325	29537568
Renal impairment	23.32	11.69	30	30604	81303	29462590
Poisoning	21.78	11.69	38	30596	9955	29533938
Interstitial lung disease	21.44	11.69	17	30617	57701	29486192
Pain in extremity	21.41	11.69	191	30443	110242	29433651
Back injury	21.38	11.69	22	30612	3462	29540431
Acute kidney injury	20.98	11.69	175	30459	265092	29278801
Arteriosclerosis coronary artery	20.16	11.69	38	30596	10567	29533326
Carpal tunnel syndrome	20.04	11.69	23	30611	4091	29539802
Pulmonary congestion	19.36	11.69	41	30593	12395	29531498
Gastrooesophageal reflux disease	19.26	11.69	74	30560	31422	29512471
Condition aggravated	19.26	11.69	82	30552	146213	29397680
Environmental exposure	19.20	11.69	8	30626	259	29543634
Intervertebral disc protrusion	18.94	11.69	33	30601	8637	29535256
Foetal exposure during pregnancy	18.50	11.69	6	30628	33861	29510032
Antasthmatic drug level	18.42	11.69	5	30629	40	29543853
Analgesic drug level	18.42	11.69	5	30629	40	29543853
Leukopenia	18.40	11.69	18	30616	55185	29488708
Road traffic accident	18.37	11.69	46	30588	15515	29528378
Mental status changes	18.13	11.69	78	30556	34849	29509044
Hypoxic-ischaemic encephalopathy	17.66	11.69	22	30612	4262	29539631
Nervousness	17.29	11.69	37	30597	11269	29532624
Blood cholesterol increased	17.27	11.69	45	30589	15550	29528343
Febrile neutropenia	16.62	11.69	60	30574	112180	29431713
Rotator cuff syndrome	16.58	11.69	23	30611	4947	29538946
Cardiomegaly	16.56	11.69	41	30593	13735	29530158
Plasma cell myeloma	16.37	11.69	79	30555	37036	29506857
Walking disability	16.27	11.69	10	30624	745	29543148
Treatment failure	16.25	11.69	9	30625	36930	29506963
Hyperlipidaemia	15.69	11.69	38	30596	12552	29531341
Pulmonary oedema	15.41	11.69	86	30548	42649	29501244
Reaction to excipient	15.31	11.69	8	30626	436	29543457
Back disorder	14.73	11.69	24	30610	5949	29537944
Thrombocytopenia	14.59	11.69	81	30553	134742	29409151
Complex regional pain syndrome	14.55	11.69	8	30626	483	29543410
Mitral valve incompetence	14.36	11.69	38	30596	13255	29530638
Haemorrhoids	14.33	11.69	35	30599	11622	29532271
Coronary artery stenosis	14.21	11.69	29	30605	8544	29535349
Thymus disorder	13.73	11.69	3	30631	8	29543885
Anger	13.71	11.69	33	30601	10857	29533036
Osteomyelitis	13.61	11.69	38	30596	13671	29530222
Liver disorder	13.35	11.69	6	30628	27743	29516150
Phantom limb syndrome	13.16	11.69	6	30628	242	29543651
Groin pain	12.82	11.69	20	30614	4778	29539115
Burning sensation	12.82	11.69	41	30593	15897	29527996
Irritability	12.69	11.69	51	30583	22101	29521792
Neutrophil count decreased	12.55	11.69	16	30618	43551	29500342
Alanine aminotransferase increased	12.55	11.69	35	30599	70909	29472984
Lower respiratory tract infection	12.34	11.69	6	30628	26496	29517397
Decreased interest	12.23	11.69	13	30621	2125	29541768
Costochondritis	12.13	11.69	7	30627	464	29543429
Dental caries	11.98	11.69	18	30616	4162	29539731
Disseminated intravascular coagulation	11.91	11.69	3	30631	19977	29523916
Myofascial pain syndrome	11.89	11.69	6	30628	304	29543589
Bronchitis	11.86	11.69	72	30562	36796	29507097
Injury	11.85	11.69	45	30589	19001	29524892
Product use issue	11.84	11.69	22	30612	51422	29492471
Atelectasis	11.84	11.69	39	30595	15353	29528540
Learning disability	11.74	11.69	6	30628	312	29543581

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	1552.88	10.42	1478	62606	222936	64211712
Toxicity to various agents	633.26	10.42	1221	62863	362292	64072356
Cardio-respiratory arrest	516.87	10.42	560	63524	97833	64336815
Cholecystitis chronic	403.31	10.42	193	63891	9094	64425554
Drug abuse	371.24	10.42	551	63533	131823	64302825
Respiratory arrest	319.81	10.42	325	63759	52660	64381988
Accidental overdose	245.91	10.42	229	63855	33328	64401320
Emotional distress	222.79	10.42	224	63860	35814	64398834
Intentional product misuse	218.52	10.42	312	63772	71983	64362665
Drug hypersensitivity	204.01	10.42	608	63476	237207	64197441
Injury	193.78	10.42	258	63826	55734	64378914
Anxiety	182.24	10.42	527	63557	202122	64232526
Gallbladder disorder	152.09	10.42	130	63954	16900	64417748
Depression	146.17	10.42	457	63627	182834	64251814
Off label use	143.80	10.42	256	63828	632550	63802098
Cardiac arrest	140.67	10.42	403	63681	153661	64280987
Drug abuser	138.79	10.42	81	64003	5727	64428921
Cholelithiasis	136.87	10.42	196	63888	45310	64389338
Drug dependence	134.91	10.42	166	63918	33146	64401502
Death	119.44	10.42	854	63230	481851	63952797
Overdose	113.75	10.42	383	63701	159183	64275465
Accidental death	97.15	10.42	55	64029	3670	64430978
Biliary dyskinesia	96.04	10.42	47	64037	2325	64432323
Deep vein thrombosis	95.80	10.42	275	63809	104907	64329741
Drug withdrawal syndrome	94.41	10.42	135	63949	31156	64403492
Contraindicated product administered	90.07	10.42	4	64080	107825	64326823
Inadequate analgesia	80.85	10.42	50	64034	3928	64430720
Coronary artery disease	79.98	10.42	182	63902	60251	64374397
Infusion related reaction	79.37	10.42	32	64052	164435	64270213
Gallbladder injury	79.19	10.42	33	64051	1115	64433533
Maternal exposure during pregnancy	78.65	10.42	4	64080	95880	64338768
Respiratory depression	74.96	10.42	104	63980	23339	64411309
Pyrexia	74.76	10.42	294	63790	558350	63876298
Synovitis	73.01	10.42	7	64077	99083	64335565
Drug intolerance	69.72	10.42	51	64033	187941	64246707
C-reactive protein increased	66.62	10.42	8	64076	94901	64339747
Neutropenia	57.83	10.42	93	63991	239531	64195117
Lower respiratory tract infection	57.36	10.42	12	64072	94602	64340046
Treatment failure	54.31	10.42	24	64060	116792	64317856
Drug ineffective	53.46	10.42	556	63528	839691	63594957
Insomnia	51.02	10.42	354	63730	197482	64237166
Chest pain	48.88	10.42	401	63683	235579	64199069
Hand deformity	47.41	10.42	4	64080	62767	64371881
Poisoning	47.31	10.42	81	64003	21798	64412850
Cardiac failure	46.41	10.42	38	64046	132335	64302313
Product use in unapproved indication	46.02	10.42	65	64019	176553	64258095
Pulmonary embolism	45.77	10.42	275	63809	146081	64288567
Pain	45.45	10.42	787	63297	552724	63881924
Febrile neutropenia	45.10	10.42	73	64011	187584	64247064
Drug interaction	44.93	10.42	196	63888	361887	64072761
Gallbladder hypofunction	44.86	10.42	17	64067	445	64434203
Renal impairment	43.44	10.42	42	64042	134975	64299673
Gun shot wound	42.83	10.42	21	64063	1043	64433605
Joint swelling	41.96	10.42	95	63989	215287	64219361
Drug tolerance	41.64	10.42	40	64044	6045	64428603
Interstitial lung disease	41.02	10.42	23	64061	97709	64336939
Back pain	40.98	10.42	404	63680	249767	64184881
Drug screen positive	39.84	10.42	38	64046	5691	64428957
Mental status changes	38.50	10.42	141	63943	61021	64373627
Systemic lupus erythematosus	37.59	10.42	15	64069	77597	64357051
Myocardial infarction	36.61	10.42	286	63798	165535	64269113
Thrombocytopenia	35.75	10.42	109	63975	223692	64210956
Leukopenia	35.56	10.42	29	64055	101213	64333435
Hepatic function abnormal	35.38	10.42	10	64074	64303	64370345
Rash	35.27	10.42	289	63795	458260	63976388
Acute kidney injury	35.07	10.42	282	63802	448958	63985690
Cerebrovascular accident	34.74	10.42	245	63839	137338	64297310
Gamma-glutamyltransferase increased	34.26	10.42	4	64080	48506	64386142
Pericarditis	33.87	10.42	10	64074	62506	64372142
Cholestasis	33.50	10.42	3	64081	44869	64389779
Condition aggravated	33.26	10.42	225	63859	372201	64062447
Exposure during pregnancy	33	10.42	18	64066	77657	64356991
Pain in extremity	32.88	10.42	452	63632	302633	64132015
Nasopharyngitis	32.39	10.42	94	63990	195979	64238669
Biliary colic	32.20	10.42	27	64057	3417	64431231
Scar	32.18	10.42	52	64032	13346	64421302
Glossodynia	32.16	10.42	12	64072	64684	64369964
Back injury	31.95	10.42	39	64045	7718	64426930
Gastrooesophageal reflux disease	31.81	10.42	165	63919	82978	64351670
Drug reaction with eosinophilia and systemic symptoms	30.63	10.42	8	64076	54209	64380439
Road traffic accident	30.53	10.42	83	64001	30662	64403986
Intervertebral disc protrusion	30.32	10.42	64	64020	20127	64414521
Anhedonia	29.97	10.42	51	64033	13655	64420993
Dependence	29.09	10.42	21	64063	2134	64432514
Hypersensitivity	29.06	10.42	99	63985	196353	64238295
Ventricular hypertrophy	28.87	10.42	34	64050	6482	64428166
Gallbladder cholesterolosis	28.46	10.42	13	64071	550	64434098
Arteriosclerosis	28.24	10.42	54	64030	15823	64418825
Substance abuse	27.89	10.42	40	64044	9252	64425396
Eosinophilia	27.24	10.42	3	64081	38073	64396575
Erythema	27.17	10.42	95	63989	186975	64247673
Product use issue	27.10	10.42	70	64014	151645	64283003
Hyperlipidaemia	26.91	10.42	66	64018	22910	64411738
Cholesterosis	26.90	10.42	11	64073	354	64434294
Muscle spasms	26.71	10.42	235	63849	140788	64293860
Toxic epidermal necrolysis	26.41	10.42	3	64081	37163	64397485
Uterine perforation	25.18	10.42	30	64054	5790	64428858
Helicobacter infection	25.11	10.42	4	64080	38358	64396290
Lactic acidosis	24.99	10.42	15	64069	61395	64373253
Cholecystectomy	24.73	10.42	35	64049	7997	64426651
Hyponatraemia	24.58	10.42	71	64013	148268	64286380
Feeling abnormal	24.46	10.42	221	63863	133381	64301267
Intervertebral disc degeneration	23.80	10.42	45	64039	13075	64421573
Nervousness	23.77	10.42	74	64010	29482	64405166
Cholecystitis	23.63	10.42	57	64027	19579	64415069
Hypoaesthesia	23.41	10.42	226	63858	138882	64295766
Hepatocellular injury	23.15	10.42	8	64076	45227	64389421
Rash maculo-papular	22.91	10.42	9	64075	47017	64387631
Rotator cuff syndrome	22.55	10.42	42	64042	12065	64422583
Hepatic enzyme increased	22.41	10.42	61	64023	129882	64304766
Rheumatoid factor positive	22.08	10.42	4	64080	34934	64399714
Arteriosclerosis coronary artery	21.92	10.42	48	64036	15481	64419167
Hyperkalaemia	21.87	10.42	42	64042	101087	64333561
General physical health deterioration	21.63	10.42	117	63967	204308	64230340
Peripheral vascular disorder	21.41	10.42	31	64053	7230	64427418
Wound	21.07	10.42	27	64057	76450	64358198
Septic shock	20.93	10.42	46	64038	105391	64329257
Coronary artery stenosis	20.93	10.42	39	64045	11209	64423439
Stomatitis	20.80	10.42	49	64035	109556	64325092
Acute lung injury	20.69	10.42	19	64065	2712	64431936
Bone marrow failure	20.53	10.42	11	64073	47941	64386707
Neutrophil count decreased	20.50	10.42	28	64056	77168	64357480
Tarsal tunnel syndrome	20.43	10.42	10	64074	495	64434153
Drug-induced liver injury	20.29	10.42	11	64073	47632	64387016
Drug resistance	20.17	10.42	5	64079	35097	64399551
Chronic obstructive pulmonary disease	20.00	10.42	130	63954	70918	64363730
Spinal osteoarthritis	19.87	10.42	44	64040	14297	64420351
Migraine	19.72	10.42	118	63966	62559	64372089
Multiple organ dysfunction syndrome	19.51	10.42	45	64039	101368	64333280
Infection	19.46	10.42	106	63978	184774	64249874
Mental disorder	19.26	10.42	64	64020	26381	64408267
Lumbar radiculopathy	19.01	10.42	15	64069	1742	64432906
Electrocardiogram QT prolonged	18.98	10.42	31	64053	79417	64355231
Altered state of consciousness	18.89	10.42	7	64077	37895	64396753
Blood pressure systolic increased	18.86	10.42	13	64071	49440	64385208
Antasthmatic drug level	18.63	10.42	5	64079	40	64434608
Rheumatoid arthritis	18.52	10.42	92	63992	164202	64270446
Pulmonary congestion	18.48	10.42	59	64025	23821	64410827
Analgesic drug level	18.21	10.42	5	64079	44	64434604
Pancytopenia	18.09	10.42	77	64007	143232	64291416
Thrombosis	17.94	10.42	126	63958	70516	64364132
Memory impairment	17.92	10.42	146	63938	85536	64349112
Mitral valve incompetence	17.89	10.42	61	64023	25477	64409171
Liver disorder	17.85	10.42	16	64068	53335	64381313
Emotional disorder	17.83	10.42	39	64045	12568	64422080
Pneumocystis jirovecii pneumonia	17.82	10.42	3	64081	27631	64407017
Back disorder	17.79	10.42	34	64050	9956	64424692
Purpura senile	17.38	10.42	9	64075	502	64434146
Sepsis	17.29	10.42	146	63938	230195	64204453
Environmental exposure	17.26	10.42	8	64076	350	64434298
Oxygen saturation decreased	17.24	10.42	52	64032	107124	64327524
Epilepsy	17.04	10.42	6	64078	33525	64401123
Inflammation	17.03	10.42	24	64060	65276	64369372
Carpal tunnel syndrome	17.00	10.42	44	64040	15784	64418864
Blood pressure fluctuation	16.83	10.42	16	64068	51855	64382793
Melaena	16.82	10.42	17	64067	53531	64381117
Transaminases increased	16.64	10.42	12	64072	44582	64390066
Angina unstable	16.62	10.42	43	64041	15424	64419224
Blood cholesterol increased	16.22	10.42	95	63989	49971	64384677
Cardiomegaly	16.09	10.42	56	64028	23628	64411020
Liver injury	15.83	10.42	5	64079	29927	64404721
Accident	15.67	10.42	26	64058	6820	64427828
Platelet count decreased	15.10	10.42	101	63983	167610	64267038
Angioedema	14.88	10.42	24	64060	61797	64372851
Fear	14.86	10.42	49	64035	20122	64414526
Muscle injury	14.74	10.42	4	64080	26433	64408215
Discomfort	14.68	10.42	37	64047	80841	64353807
Chronic fatigue syndrome	14.68	10.42	11	64073	1184	64433464
Amnesia	14.63	10.42	90	63994	48179	64386469
Postinfarction angina	14.59	10.42	4	64080	35	64434613
Intervertebral disc disorder	14.58	10.42	20	64064	4437	64430211
Peptic ulcer	14.53	10.42	22	64062	5341	64429307
Anaphylactic shock	14.45	10.42	6	64078	30322	64404326
Respiratory disorder	14.44	10.42	9	64075	36102	64398546
Anaphylactic reaction	14.43	10.42	29	64055	68635	64366013
Major depression	14.41	10.42	27	64057	7789	64426859
Multiple injuries	14.26	10.42	17	64067	3282	64431366
Folliculitis	14.26	10.42	6	64078	30071	64404577
COVID-19	14.13	10.42	27	64057	65113	64369535
Copper deficiency	14.09	10.42	5	64079	108	64434540
Lymphopenia	14.09	10.42	4	64080	25653	64408995
Obstructive airways disorder	13.92	10.42	3	64081	23182	64411466
Neurotoxicity	13.76	10.42	5	64079	27399	64407249
Extradural haematoma	13.61	10.42	15	64069	2661	64431987
Irritability	13.41	10.42	72	64012	36674	64397974
Crying	13.22	10.42	47	64037	20043	64414605
Drug eruption	13.13	10.42	10	64074	36126	64398522
Cerebral haemorrhage	13.10	10.42	19	64065	51071	64383577
Stevens-Johnson syndrome	13.06	10.42	9	64075	34240	64400408
Withdrawal syndrome	13.00	10.42	52	64032	23440	64411208
Pulmonary infarction	12.95	10.42	16	64068	3206	64431442
Sleep disorder due to general medical condition, insomnia type	12.84	10.42	5	64079	26265	64408383
Resorption bone increased	12.70	10.42	10	64074	1158	64433490
Opiates positive	12.69	10.42	9	64075	889	64433759
Cholecystitis acute	12.64	10.42	32	64052	11328	64423320
Blood creatinine increased	12.61	10.42	81	64003	135701	64298947
Respiratory muscle weakness	12.56	10.42	6	64078	281	64434367
Hypoxic-ischaemic encephalopathy	12.32	10.42	24	64060	7128	64427520
Hernia	11.96	10.42	35	64049	13483	64421165
Cytokine release syndrome	11.90	10.42	3	64081	20826	64413822
Malabsorption	11.84	10.42	18	64066	4385	64430263
Dyspepsia	11.83	10.42	127	63957	80185	64354463
Neck injury	11.80	10.42	13	64071	2305	64432343
Heart rate decreased	11.79	10.42	23	64061	55044	64379604
Cardiogenic shock	11.75	10.42	9	64075	32418	64402230
Urticaria	11.67	10.42	92	63992	147225	64287423
Therapeutic product effect decreased	11.66	10.42	67	64017	115284	64319364
Hepatitis	11.64	10.42	17	64067	45565	64389083
Phantom limb syndrome	11.58	10.42	6	64078	335	64434313
Therapeutic product effect increased	11.50	10.42	10	64074	1330	64433318
Endometriosis	11.44	10.42	14	64070	2778	64431870
Post concussion syndrome	11.43	10.42	7	64077	540	64434108
Osteomyelitis	11.43	10.42	56	64028	27531	64407117
Circulatory collapse	11.43	10.42	10	64074	33722	64400926
Pulmonary oedema	11.40	10.42	124	63960	78550	64356098
Nausea	11.40	10.42	917	63167	784883	63649765
Muscle atrophy	11.39	10.42	28	64056	9730	64424918
Transient ischaemic attack	11.33	10.42	79	64005	44103	64390545
Complex regional pain syndrome	11.32	10.42	11	64073	1685	64432963
Osteoarthritis	11.19	10.42	104	63980	63232	64371416
Snake bite	11.18	10.42	3	64081	24	64434624
Tachycardia	11.13	10.42	95	63989	149484	64285164
Polyneuropathy	11.11	10.42	3	64081	19891	64414757
Respiratory distress	11.08	10.42	22	64062	52309	64382339
Laryngeal pain	10.98	10.42	20	64064	5648	64429000
Tooth loss	10.81	10.42	21	64063	6226	64428422
Myofascial pain syndrome	10.78	10.42	11	64073	1787	64432861
Neuropathy peripheral	10.64	10.42	170	63914	117355	64317293
Transverse sinus thrombosis	10.63	10.42	7	64077	613	64434035
Product complaint	10.62	10.42	31	64053	11923	64422725
Tendon disorder	10.61	10.42	21	64063	6311	64428337
Unresponsive to stimuli	10.60	10.42	86	63998	50307	64384341
Paraesthesia	10.51	10.42	190	63894	134332	64300316
Anger	10.50	10.42	37	64047	15704	64418944
Neutropenic sepsis	10.47	10.42	5	64079	23267	64411381
Coronary artery occlusion	10.46	10.42	34	64050	13857	64420791
Head injury	10.43	10.42	62	64022	32780	64401868
Fibromyalgia	10.43	10.42	66	64018	35665	64398983
Bronchopulmonary aspergillosis	10.43	10.42	3	64081	19082	64415566

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	R05DA03	RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS Opium alkaloids and derivatives
FDA MoA	N0000000174	Opioid Agonists
MeSH PA	D000700	Analgesics
MeSH PA	D000701	Analgesics, Opioid
MeSH PA	D000996	Antitussive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D009294	Narcotics
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D019141	Respiratory System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35482	narcotic analgesic
CHEBI has role	CHEBI:51177	anti-tussive
CHEBI has role	CHEBI:55322	mu-opioid agonists
FDA EPC	N0000175690	Opioid Agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Pain	indication	22253000
Cough	indication	49727002
Allergic rhinitis	indication	61582004
Nasal discharge	indication	64531003
Nasal congestion	indication	68235000
Rhinitis	indication	70076002	DOID:4483
Common cold	indication	82272006	DOID:10459
Brain damage	contraindication	2470005
Ocular hypertension	contraindication	4210003	DOID:9282
Tachyarrhythmia	contraindication	6285003
Suicidal thoughts	contraindication	6471006
Dependent drug abuse	contraindication	6525002
Urinary tract obstruction	contraindication	7163005	DOID:5200
Alcoholism	contraindication	7200002
Alcohol withdrawal delirium	contraindication	8635005
Peptic ulcer	contraindication	13200003	DOID:750
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Asthenia	contraindication	13791008
Hyperkalemia	contraindication	14140009
Severe chronic ulcerative colitis	contraindication	14311001
Constipation	contraindication	14760008	DOID:2089
Mood swings	contraindication	18963009
Myocardial infarction	contraindication	22298006	DOID:5844
Inflammatory bowel disease	contraindication	24526004	DOID:0050589
Ventricular tachycardia	contraindication	25569003
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Hypercapnia	contraindication	29596007
Dehydration	contraindication	34095006
Hyperthyroidism	contraindication	34486009	DOID:7998
Acute hepatitis	contraindication	37871000
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Gastrointestinal ulcer	contraindication	40845000
Hypothyroidism	contraindication	40930008	DOID:1459
Complete trisomy 21 syndrome	contraindication	41040004	DOID:14250
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Bradycardia	contraindication	48867003
Acidosis	contraindication	51387008
Gastrointestinal perforation	contraindication	51875005
Vitamin K deficiency	contraindication	52675005	DOID:11249
Nasal polyp	contraindication	52756005
Coronary arteriosclerosis	contraindication	53741008	DOID:3393
Paralytic ileus	contraindication	55525008	DOID:8442
Peptic reflux disease	contraindication	57643001
Acute nephropathy	contraindication	58574008
Metabolic acidosis	contraindication	59455009
Hepatic failure	contraindication	59927004
Ulcerative colitis	contraindication	64766004	DOID:8577
Blood coagulation disorder	contraindication	64779008	DOID:1247
Arterial thrombosis	contraindication	65198009
Drug AND/OR toxin-induced diarrhea	contraindication	65979008
Substance abuse	contraindication	66214007
Benign intracranial hypertension	contraindication	68267002	DOID:11459
Poisoning by acetaminophen	contraindication	70273001
Arteriosclerotic vascular disease	contraindication	72092001
Diabetes mellitus	contraindication	73211009	DOID:9351
Factor II deficiency	contraindication	73975000
Reye's syndrome	contraindication	74351001	DOID:14525
Gastrointestinal hemorrhage	contraindication	74474003
Urethral stricture	contraindication	76618002
Thrombotic thrombocytopenic purpura	contraindication	78129009	DOID:10772
Spastic paralysis	contraindication	78403003
Disturbance of salivary secretion	contraindication	78948009
Decreased respiratory function	contraindication	80954004
Injury of head	contraindication	82271004
Chronic idiopathic constipation	contraindication	82934008
Cor pulmonale	contraindication	83291003	DOID:8515
Hiatal hernia	contraindication	84089009	DOID:12642
Pulmonary emphysema	contraindication	87433001
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Hemophilia	contraindication	90935002
Myasthenia gravis	contraindication	91637004	DOID:437
Anemia due to enzyme deficiency	contraindication	111577008
Acute abdominal pain	contraindication	116290004
Gastrointestinal obstruction	contraindication	126765001
Neoplasm of brain	contraindication	126952004	DOID:1319
von Willebrand disorder	contraindication	128105004	DOID:12531
Seizure disorder	contraindication	128613002
Autonomic dysreflexia	contraindication	129618003
Bleeding	contraindication	131148009
Drug-induced psychosis	contraindication	191483003	DOID:1742
Partial atrioventricular block	contraindication	195039008
Acute pancreatitis	contraindication	197456007	DOID:2913
Coronary artery bypass graft	contraindication	232717009
Myocardial dysfunction	contraindication	233928007
Disease of liver	contraindication	235856003	DOID:409
Hyporeninemic hypoaldosteronism	contraindication	236464008
Bladder outflow obstruction	contraindication	236645006
Morbid obesity	contraindication	238136002	DOID:11981
Rhabdomyolysis	contraindication	240131006
Pyloric obstruction	contraindication	244815007
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Anemia	contraindication	271737000	DOID:2355
Drowsy	contraindication	271782001
Exacerbation of asthma	contraindication	281239006
Pregnancy, function	contraindication	289908002
Lesion of brain	contraindication	301766008
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Coma	contraindication	371632003
Primary adrenocortical insufficiency	contraindication	373662000
Operation on gastrointestinal tract	contraindication	386621005
Hypoxia	contraindication	389086002
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Cardiovascular event risk	contraindication	395112001
Gastric ulcer	contraindication	397825006	DOID:10808
Breastfeeding (mother)	contraindication	413712001
Chronic lung disease	contraindication	413839001
Disorder of coronary artery	contraindication	414024009
Traumatic injury	contraindication	417746004
Central nervous system depression	contraindication	418072004
Dysfunction of sphincter of Oddi	contraindication	430887001
Hypertensive urgency	contraindication	443482000
Acute erosive gastritis	contraindication	444926003
Smokes tobacco daily	contraindication	449868002
Acute Thromboembolic Stroke	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.64	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	10130591	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8309060	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	10130591	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8309060	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	10130591	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8309060	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	10130591	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8309060	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	10130591	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8309060	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	10130591	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8309060	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	10130591	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8309060	Nov. 20, 2023	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	11304909	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9095614	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492390	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492391	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9545380	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	11304909	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9095614	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492390	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492391	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9545380	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	11304909	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9095614	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492390	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492391	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9545380	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	11304909	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9095614	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492390	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492391	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9545380	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	11304909	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9095614	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492390	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492391	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9545380	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	11304909	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9095614	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492390	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492391	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9545380	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	11304909	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9095614	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492390	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9492391	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	9545380	Aug. 24, 2027	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
100MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8808740	Dec. 21, 2031	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
120MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8808740	Dec. 21, 2031	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
20MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8808740	Dec. 21, 2031	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
30MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8808740	Dec. 21, 2031	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
40MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8808740	Dec. 21, 2031	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
60MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8808740	Dec. 21, 2031	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
80MG	HYSINGLA ER	PURDUE PHARMA LP	N206627	Nov. 20, 2014	RX	TABLET, EXTENDED RELEASE	ORAL	8808740	Dec. 21, 2031	MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10028946	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10456393	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10722511	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9265760	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9326982	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9333201	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9339499	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9421200	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9433619	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9610286	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10028946	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10456393	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10722511	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9265760	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9326982	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9333201	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9339499	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9421200	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9433619	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9610286	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10028946	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10456393	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10722511	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9265760	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9326982	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9333201	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9339499	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9421200	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9433619	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9610286	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10028946	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10456393	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10722511	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9265760	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9326982	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9333201	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9339499	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9421200	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9433619	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9610286	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10028946	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10456393	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10722511	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9265760	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9326982	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9333201	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9339499	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9421200	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9433619	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9610286	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10028946	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10456393	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10722511	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9265760	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9326982	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9333201	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9339499	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9421200	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9433619	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9610286	July 25, 2033	TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10092559	Sept. 12, 2034	TREATMENT OF PAIN
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9452163	Sept. 12, 2034	TREATMENT OF PAIN
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9486451	Sept. 12, 2034	TREATMENT OF PAIN
10MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9713611	Sept. 12, 2034	TREATMENT OF PAIN
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10092559	Sept. 12, 2034	TREATMENT OF PAIN
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9452163	Sept. 12, 2034	TREATMENT OF PAIN
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9486451	Sept. 12, 2034	TREATMENT OF PAIN
15MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9713611	Sept. 12, 2034	TREATMENT OF PAIN
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10092559	Sept. 12, 2034	TREATMENT OF PAIN
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9452163	Sept. 12, 2034	TREATMENT OF PAIN
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9486451	Sept. 12, 2034	TREATMENT OF PAIN
20MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9713611	Sept. 12, 2034	TREATMENT OF PAIN
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10092559	Sept. 12, 2034	TREATMENT OF PAIN
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9452163	Sept. 12, 2034	TREATMENT OF PAIN
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9486451	Sept. 12, 2034	TREATMENT OF PAIN
30MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9713611	Sept. 12, 2034	TREATMENT OF PAIN
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10092559	Sept. 12, 2034	TREATMENT OF PAIN
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9452163	Sept. 12, 2034	TREATMENT OF PAIN
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9486451	Sept. 12, 2034	TREATMENT OF PAIN
40MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9713611	Sept. 12, 2034	TREATMENT OF PAIN
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	10092559	Sept. 12, 2034	TREATMENT OF PAIN
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9452163	Sept. 12, 2034	TREATMENT OF PAIN
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9486451	Sept. 12, 2034	TREATMENT OF PAIN
50MG	ZOHYDRO ER	RECRO GAINESVILLE	N202880	Oct. 25, 2013	DISCN	CAPSULE, EXTENDED RELEASE	ORAL	9713611	Sept. 12, 2034	TREATMENT OF PAIN
200MG/5ML;2.5MG/5ML	OBREDON	SOVEREIGN PHARMS	N205474	Nov. 14, 2014	DISCN	SOLUTION	ORAL	10105324	Nov. 13, 2035	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
200MG/5ML;2.5MG/5ML	OBREDON	SOVEREIGN PHARMS	N205474	Nov. 14, 2014	DISCN	SOLUTION	ORAL	9549907	Nov. 13, 2035	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4
200MG/5ML;2.5MG/5ML	OBREDON	SOVEREIGN PHARMS	N205474	Nov. 14, 2014	DISCN	SOLUTION	ORAL	9808431	Nov. 13, 2035	A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	AGONIST	Ki	8.02		CHEMBL	CHEMBL
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN	AGONIST	Ki	6.59		CHEMBL

External reference:

ID	Source
4018165	VUID
N0000146502	NUI
D03725	KEGG_DRUG
34195-34-1	SECONDARY_CAS_RN
4018165	VANDF
4018473	VANDF
4019409	VANDF
C0020264	UMLSCUI
CHEBI:5779	CHEBI
CHEMBL1457	ChEMBL_ID
DB00956	DRUGBANK_ID
CHEMBL3989677	ChEMBL_ID
CHEMBL2062267	ChEMBL_ID
D006853	MESH_DESCRIPTOR_UI
5284569	PUBCHEM_CID
7081	IUPHAR_LIGAND_ID
1700	INN_ID
6YKS4Y3WQ7	UNII
142439	RXNORM
13945	MMSL
4835	MMSL
4836	MMSL
d03075	MMSL
001554	NDDF
001555	NDDF
001556	NDDF
20320002	SNOMEDCT_US
372671002	SNOMEDCT_US
3874004	SNOMEDCT_US
736862006	SNOMEDCT_US
CHEMBL1201470	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0772	SOLUTION	7.50 mg	ORAL	ANDA	30 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0772	SOLUTION	7.50 mg	ORAL	ANDA	30 sections
Zamicet	HUMAN PRESCRIPTION DRUG LABEL	2	0121-1542	SOLUTION	5 mg	ORAL	ANDA	30 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0121-1544	SOLUTION	5 mg	ORAL	ANDA	30 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0121-1544	SOLUTION	5 mg	ORAL	ANDA	30 sections
Zamicet	HUMAN PRESCRIPTION DRUG LABEL	2	0121-2313	SOLUTION	10 mg	ORAL	ANDA	30 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0121-2316	SOLUTION	7.50 mg	ORAL	ANDA	30 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0121-2316	SOLUTION	7.50 mg	ORAL	ANDA	30 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0121-4772	SOLUTION	2.50 mg	ORAL	ANDA	30 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0121-4772	SOLUTION	2.50 mg	ORAL	ANDA	30 sections
Hydrocodone Bitartrate and Homatropine Methylbromide	HUMAN PRESCRIPTION DRUG LABEL	2	0121-4811	SYRUP	5 mg	ORAL	ANDA	35 sections
TussiCaps	HUMAN PRESCRIPTION DRUG LABEL	2	0187-0054	CAPSULE, EXTENDED RELEASE	5 mg	ORAL	ANDA	24 sections
TussiCaps	HUMAN PRESCRIPTION DRUG LABEL	2	0187-0108	CAPSULE, EXTENDED RELEASE	10 mg	ORAL	ANDA	24 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0245-0410	TABLET	5 mg	ORAL	ANDA	34 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0245-0411	TABLET	7.50 mg	ORAL	ANDA	34 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0245-0412	TABLET	10 mg	ORAL	ANDA	34 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0254-2034	TABLET	5 mg	ORAL	ANDA	34 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0254-2035	TABLET	7.50 mg	ORAL	ANDA	34 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0254-2036	TABLET	10 mg	ORAL	ANDA	34 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	HUMAN PRESCRIPTION DRUG LABEL	2	0406-0123	TABLET	5 mg	ORAL	ANDA	28 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	HUMAN PRESCRIPTION DRUG LABEL	2	0406-0124	TABLET	7.50 mg	ORAL	ANDA	28 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	HUMAN PRESCRIPTION DRUG LABEL	2	0406-0125	TABLET	10 mg	ORAL	ANDA	28 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0406-0376	TABLET	5 mg	ORAL	ANDA	27 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0406-0377	TABLET	7.50 mg	ORAL	ANDA	27 sections
Hydrocodone Bitartrate and Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0406-0378	TABLET	10 mg	ORAL	ANDA	27 sections
Hydrocodone Bitartrate And Acetaminophen	HUMAN PRESCRIPTION DRUG LABEL	2	0440-7605	TABLET	5 mg	ORAL	ANDA	30 sections
HYDROCODONE BITARTRATE AND ACETAMINOPHEN	HUMAN PRESCRIPTION DRUG LABEL	2	0440-7610	TABLET	5 mg	ORAL	ANDA	27 sections
Hydromet	HUMAN PRESCRIPTION DRUG LABEL	2	0472-1030	SOLUTION	5 mg	ORAL	ANDA	29 sections
Zamicet	HUMAN PRESCRIPTION DRUG LABEL	2	0486-0771	SOLUTION	10 mg	ORAL	ANDA	30 sections
Zamicet	HUMAN PRESCRIPTION DRUG LABEL	2	0486-4771	SOLUTION	5 mg	ORAL	ANDA	30 sections